Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A.
paper
Cited
Public
Unavailable
- Authors
- Krajewski, K M; Lewis, R A; Fuerst, D R; Turansky, C; Hinderer, S R; Garbern, J; Kamholz, J; Shy, M E
- Year
- 2000
- Journal
- Brain : a journal of neurology
- PMID
- 10869062
- DOI
- 10.1093/brain/123.7.1516
Charcot-Marie-Tooth disease type 1A (CMT1A), the most frequent form of CMT, is caused by a 1.5 Mb duplication on the short arm of chromosome 17. Patients with CMT1A typically have slowed nerve conduction velocities (NCVs), reduced compound motor and sensory nerve action potentials (CMAPs and SNAPs), distal weakness, sensory loss and decreased reflexes. In order to understand further the molecular pathogenesis of CMT1A, as well as to determine which features correlate with neurological dysfunction and might thus be amenable to treatment, we evaluated the clinical and electrophysiological phenotype in 42 patients with CMT1A. In these patients, muscle weakness, CMAP amplitudes and motor unit number estimates correlated with clinical disability, while motor NCV did not. In addition, loss of joint position sense and reduction in SNAP amplitudes also correlated with clinical disability, while sensory NCV did not. Taken together, these data strongly support the hypothesis that neurological dysfunction and clinical disability in CMT1A are caused by loss or damage to large calibre motor and sensory axons. Therapeutic approaches to ameliorate disability in CMT1A, as in amyotrophic lateral sclerosis and other neurodegenerative diseases, should thus be directed towards preventing axonal degeneration and/or promoting axonal regeneration.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Copy number variations in 6q14.1 and 5q13.2 are associated with alcohol dependence. | 2012 | 22702843 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Aberrant Molecular Myelin Architecture in Charcot-Marie-Tooth Disease Type 1A and Hereditary Neuropathy With Liability to Pressure Palsies. | Moss KR et al. | — | 2026 | → |
| An open-label single-arm phase 1/2a study to evaluate the safety and exploratory efficacy of a VM202 in patients with Charcot-Marie-Tooth disease 1A. | Kwon HM et al. | — | 2026 | → |
| Charcot-Marie-Tooth disease and related neuropathies. | Burns J et al. | — | 2026 | → |
| Genetic commonalities between rare subtypes of ALS and CMT: insights into molecular mechanisms of neurodegeneration. | Aynaashe A et al. | — | 2026 | → |
| Restless Legs Syndrome in Patients With PMP22-Related Neuropathies. | Bjelica B et al. | — | 2026 | → |
| Sonographic Muscle Thickness Assessment Correlates With Disease Burden and Progression in Charcot-Marie-Tooth 1A Disease. | Ravid B et al. | — | 2026 | → |
| A case report of a MODY6 patient coexistence with Charcot-Marie-Toothe 1A syndrome. | Wang J et al. | — | 2025 | → |
| Basic Pathological Mechanisms in Peripheral Nerve Diseases. | Schenone A et al. | — | 2025 | → |
| Characterization of a humanized mouse model of Charcot-Marie-Tooth type 1A for the discovery of human <i>PMP22</i>-targeting drugs. | Taruta A et al. | — | 2025 | → |
| Feasibility, Validity, and Reliability of the Virtual CMT Infant Toddler Scale (vCMTInfS): A Remote Evaluation of Infants/Toddlers With CMT. | Shy R et al. | — | 2025 | → |
| Performance-based and patient-reported outcome measures for custom ankle-foot orthosis users: reliability, validity, and sensitivity evidence. | Heinemann AW et al. | — | 2025 | → |
| Ultrasound Shear Wave Velocity of Peripheral Nerves: A Possible Non-Invasive Biomarker for Demyelinating Neuropathies. | Andrade RJ et al. | — | 2025 | → |
| Aberrant Molecular Myelin Architecture in Charcot-Marie-Tooth Disease Type 1A and Hereditary Neuropathy with Liability to Pressure Palsies | Moss KR et al. | — | 2024 | — |
| A study concept of expeditious clinical enrollment for genetic modifier studies in Charcot-Marie-Tooth neuropathy 1A. | Xu IRL et al. | — | 2024 | → |
| Bilateral hearing impairment as an early symptom in a patient with Charcot-Marie-Tooth Type 1: the first case report from Syria. | Hamsho S et al. | — | 2024 | → |
| Testing SIPA1L2 as a modifier of CMT1A using mouse models. | Murray GC et al. | — | 2024 | → |
| A Bioelectrical Impedance Analysis for the Assessment of Muscle Atrophy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy. | Ohyama K et al. | — | 2023 | → |
| Disease Progression in Charcot-Marie-Tooth Disease Related to MPZ Mutations: A Longitudinal Study. | Fridman V et al. | — | 2023 | → |
| Gait Pattern in Charcot-Marie-Tooth Disease Type 1A According to Disease Severity. | Park J et al. | — | 2023 | → |
| Intravenous Administration of an AAV9 Vector Ubiquitously Expressing C1orf194 Gene Improved CMT-Like Neuropathy in C1orf194<sup>-/-</sup> Mice. | Shen Z et al. | — | 2023 | → |
| Neuromuscular junction involvement in inherited motor neuropathies: genetic heterogeneity and effect of oral salbutamol treatment. | McMacken G et al. | — | 2023 | → |
| Peripheral neuropathy in mitochondrial disease. | Horvath R et al. | — | 2023 | → |
| Severe Dry Eye Disease in Charcot-Marie-Tooth Disease: A Comprehensive Case Report. | Aldihan KA et al. | — | 2023 | → |
| The systemic inhibition of the terminal complement system reduces neuroinflammation but does not improve motor function in mouse models of CMT1A with overexpressed <i>PMP22</i>. | Michailidou I et al. | — | 2023 | → |
| Validation of the parent-proxy version of the pediatric Charcot-Marie-Tooth disease quality of life instrument for children aged 0-7 years. | Wu TT et al. | — | 2023 | → |
| A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice. | Stavrou M et al. | — | 2022 | → |
| Blood biomarkers of peripheral neuropathy. | Rossor AM et al. | — | 2022 | → |
| Candidate imaging biomarkers for PMP22-related inherited neuropathies. | Roth AR et al. | — | 2022 | → |
| Colocalization Analysis of Peripheral Myelin Protein-22 and Lamin-B1 in the Schwann Cell Nuclei of Wt and TrJ Mice. | Di Tomaso MV et al. | — | 2022 | → |
| Importance of Electrodiagnostic Testing Prior to a Tethered Cord Release in a Patient with Overlapping Symptoms of Charcot-Marie-Tooth Disease. | Shields LB et al. | — | 2022 | → |
| Neurotransmission Recovery by Melatonin Measured by CMAP. | Negro S et al. | — | 2022 | → |
| Recognising the potential of large animals for modelling neuromuscular junction physiology and disease. | Cahalan SD et al. | — | 2022 | → |
| SARM1 knockout does not rescue neuromuscular phenotypes in a Charcot-Marie-Tooth disease Type 1A mouse model. | Moss KR et al. | — | 2022 | → |
| The impact of symptoms on daily life as perceived by patients with Charcot-Marie-Tooth type 1A disease. | Tozza S et al. | — | 2022 | → |
| AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A. | Gautier B et al. | — | 2021 | → |
| Application Value of the Motor Unit Number Index in Patients With Kennedy Disease. | Zhang S et al. | — | 2021 | → |
| FGF21 impedes peripheral myelin development by stimulating p38 MAPK/c-Jun axis. | Zhang Y et al. | — | 2021 | → |
| Intraepineurial fat quantification and cross-sectional area analysis of the sciatic nerve using MRI in Charcot-Marie-Tooth disease type 1A patients. | Kim HS et al. | — | 2021 | → |
| Mechanisms and Treatments in Demyelinating CMT. | Fridman V et al. | — | 2021 | → |
| Multidimensional evaluation is necessary to assess hand function in patients with Charcot-Marie-Tooth disease type 1A. | Reynaud V et al. | — | 2021 | → |
| MyelTracer: A Semi-Automated Software for Myelin <i>g</i>-Ratio Quantification. | Kaiser T et al. | — | 2021 | → |
| New evidence for secondary axonal degeneration in demyelinating neuropathies. | Moss KR et al. | — | 2021 | → |
| Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back. | Geisler S | — | 2021 | → |
| A Comparative Review of Chemotherapy-Induced Peripheral Neuropathy in In Vivo and In Vitro Models. | Eldridge S et al. | — | 2020 | → |
| Brain Plasticity in Charcot-Marie-Tooth Type 1A Patients? A Combined Structural and Diffusion MRI Study. | Pontillo G et al. | — | 2020 | → |
| Gene therapy to promote regeneration in Charcot-Marie-Tooth disease. | Sahenk Z et al. | — | 2020 | → |
| Human Tridimensional Neuronal Cultures for Phenotypic Drug Screening in Inherited Peripheral Neuropathies. | Maciel R et al. | — | 2020 | → |
| Length-dependent MRI of hereditary neuropathy with liability to pressure palsies. | Pridmore M et al. | — | 2020 | → |
| Quantitative assessment of sciatic nerve changes in Charcot-Marie-Tooth type 1A patients using magnetic resonance neurography. | Fortanier E et al. | — | 2020 | → |
| Targeting the programmed axon degeneration pathway as a potential therapeutic for Charcot-Marie-Tooth disease. | Moss KR et al. | — | 2020 | → |
| The Association Between Phosphorylated Neurofilament Heavy Chain (pNF-H) and Small Fiber Neuropathy (SFN) in Patients with Impaired Glucose Tolerance. | Li YP et al. | — | 2020 | → |
| The ubiquitous role of mitochondria in Parkinson and other neurodegenerative diseases. | Theocharopoulou G | — | 2020 | → |
| Transmembrane protease serine 5: a novel Schwann cell plasma marker for CMT1A. | Wang H et al. | — | 2020 | → |
| A Case Report on Charcot-Marie-Tooth Disease with a Novel Periaxin Gene Mutation. | Datta S et al. | — | 2019 | → |
| Body composition and its association with physical performance, quality of life, and clinical indictors in Charcot-Marie-Tooth disease: a pilot study. | Hackett D et al. | — | 2019 | → |
| Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. | Kagiava A et al. | — | 2019 | → |
| Genetic spectrum and clinical profiles in a southeast Chinese cohort of Charcot-Marie-Tooth disease. | Chen CX et al. | — | 2019 | → |
| Hidden Charcot-Marie-Tooth 1A as Revealed by Peripheral Nerve Imaging. | Shibuya K et al. | — | 2019 | → |
| Insights into the pathogenesis of ATP1A1-related CMT disease using patient-specific iPSCs. | Manganelli F et al. | — | 2019 | → |
| Morphometric analysis of peripheral myelinated nerve fibers through deep learning. | Moiseev D et al. | — | 2019 | → |
| Multiparametric rapid screening of neuronal process pathology for drug target identification in HSP patient-specific neurons. | Rehbach K et al. | — | 2019 | → |
| Nerve size correlates with clinical severity in Charcot-Marie-Tooth disease 1A. | Zanette G et al. | — | 2019 | → |
| Phrenic nerve involvement and respiratory muscle weakness in patients with Charcot-Marie-Tooth disease 1A. | Spiesshoefer J et al. | — | 2019 | → |
| Schwann Cell and the Pathogenesis of Charcot-Marie-Tooth Disease. | Murakami T et al. | — | 2019 | → |
| Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies. | Svaren J et al. | — | 2019 | → |
| Successful treatment of nasopharyngeal cancer using radiotherapy with concurrent cetuximab in a patient with Charcot-Marie-Tooth disease. | Budure AN et al. | — | 2019 | → |
| Surgical outcomes of cavovarus foot deformity in children with Charcot-Marie-Tooth disease. | Lin T et al. | — | 2019 | → |
| An In Vitro Model of Charcot-Marie-Tooth Disease Type 4B2 Provides Insight Into the Roles of MTMR13 and MTMR2 in Schwann Cell Myelination. | Robinson DC et al. | — | 2018 | → |
| Antisense oligonucleotides offer hope to patients with Charcot-Marie-Tooth disease type 1A. | Shy ME | — | 2018 | → |
| DHTKD1 Deficiency Causes Charcot-Marie-Tooth Disease in Mice. | Xu WY et al. | — | 2018 | → |
| Efficacy of exogenous pyruvate in Trembler<sup>J</sup> mouse model of Charcot-Marie-Tooth neuropathy. | Sahenk Z et al. | — | 2018 | → |
| Functional MRI and laser-evoked potentials evaluation in Charcot-Marie-Tooth syndrome. | De Salvo S et al. | — | 2018 | → |
| Genome expression profiling predicts the molecular mechanism of peripheral myelination. | Wu X | — | 2018 | → |
| In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration. | Pollari E et al. | — | 2018 | → |
| Ipsilateral proprioceptive neuromuscular facilitation patterns improve overflow and reduce foot drop in patients with demyelinating polyneuropathy. | Nakada CS et al. | — | 2018 | → |
| Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients. | Tozza S et al. | — | 2018 | → |
| Pathological classification of equine recurrent laryngeal neuropathy. | Draper ACE et al. | — | 2018 | → |
| PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. | Zhao HT et al. | — | 2018 | → |
| Structure, function, and regulation of mitofusin-2 in health and disease. | Chandhok G et al. | — | 2018 | → |
| Tied up: Does altering phosphoinositide-mediated membrane trafficking influence neurodegenerative disease phenotypes? | Nadiminti SSP et al. | — | 2018 | → |
| Use of 3D Prints to Compare the Efficacy of Three Different Calcaneal Osteotomies for the Correction of Heel Varus. | Pfeffer GB et al. | — | 2018 | → |
| A case report of hereditary neuropathy with liability to pressure palsies accompanied by type 2 diabetes mellitus and psoriasis. | Li J et al. | — | 2017 | → |
| Anatomical distributional defects in mutant genes associated with dominant intermediate Charcot-Marie-Tooth disease type C in an adenovirus-mediated mouse model. | Lee S et al. | — | 2017 | → |
| Axonal domain disorganization in Caspr1 and Caspr2 mutant myelinated axons affects neuromuscular junction integrity, leading to muscle atrophy. | Saifetiarova J et al. | — | 2017 | → |
| Blink reflex role in algorithmic genetic testing of inherited polyneuropathies. | Wang W et al. | — | 2017 | → |
| Caveats in the Established Understanding of CMT1A. | Li J | — | 2017 | → |
| LRSAM1-mediated ubiquitylation is disrupted in axonal Charcot-Marie-Tooth disease 2P. | Hakonen JE et al. | — | 2017 | → |
| Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: a randomised, double-blind, sham-controlled trial. | Burns J et al. | — | 2017 | → |
| Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. | Imai S et al. | — | 2017 | → |
| A WHEP Domain Regulates the Dynamic Structure and Activity of Caenorhabditis elegans Glycyl-tRNA Synthetase. | Chang CY et al. | — | 2016 | → |
| Charcot-Marie-Tooth 1A: A narrative review with clinical and anatomical perspectives. | McGrath MC | — | 2016 | → |
| Management of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approach. | McCorquodale D et al. | — | 2016 | → |
| Nerve conduction velocity in CMT1A: what else can we tell? | Manganelli F et al. | — | 2016 | → |
| Neurophysiological profile of peripheral neuropathy associated with childhood mitochondrial disease. | Menezes MP et al. | — | 2016 | → |
| Stimulation-induced Ca(2+) influx at nodes of Ranvier in mouse peripheral motor axons. | Zhang Z et al. | — | 2016 | → |
| Structural and Functional Abnormalities of the Neuromuscular Junction in the Trembler-J Homozygote Mouse Model of Congenital Hypomyelinating Neuropathy. | Scurry AN et al. | — | 2016 | → |
| Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. | Sociali G et al. | — | 2016 | → |
| Validation of differential GDAP1 DNA methylation in alcohol dependence and its potential function as a biomarker for disease severity and therapy outcome. | Brückmann C et al. | — | 2016 | → |
| Ascorbic acid for the treatment of Charcot-Marie-Tooth disease. | Gess B et al. | — | 2015 | → |
| Blocking bad. | Scherer SS | — | 2015 | → |
| Coexistence of Charcot Marie Tooth disease type 1A and diabetes in Taiwan: A clinicopathological study. | Chao HC et al. | — | 2015 | → |
| Coexistent Charcot-Marie-Tooth type 1A and type 2 diabetes mellitus neuropathies in a Chinese family. | Sun AP et al. | — | 2015 | → |
| Human Neuroma-in-Continuity Contains Focal Deficits in Myelination. | van Vliet AC et al. | — | 2015 | → |
| Hyperglycemia Promotes Schwann Cell De-differentiation and De-myelination via Sorbitol Accumulation and Igf1 Protein Down-regulation. | Hao W et al. | — | 2015 | → |
| In Vivo Confocal Microscopy of the Human Cornea in the Assessment of Peripheral Neuropathy and Systemic Diseases. | Wang EF et al. | — | 2015 | → |
| Molecular and clinical features of inherited neuropathies due to PMP22 duplication. | Watila MM et al. | — | 2015 | → |
| Molecular regulators of nerve conduction - Lessons from inherited neuropathies and rodent genetic models. | Li J | — | 2015 | → |
| Neurological associations in auditory neuropathy spectrum disorder: Results from a tertiary hospital in South India. | Lepcha A et al. | — | 2015 | → |
| Normal nerve striations are altered in the trembler-J mouse, a model of Charcot-Marie-Tooth disease. | Power BJ et al. | — | 2015 | → |
| Respiratory dysfunction in Charcot-Marie-Tooth disease type 1A. | de Carvalho Alcântara M et al. | — | 2015 | → |
| Small nerve fiber involvement in CMT1A. | Nolano M et al. | — | 2015 | → |
| AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy. | Sahenk Z et al. | — | 2014 | → |
| Amount and intensity of daily living activities in Charcot-Marie-Tooth 1A patients. | Menotti F et al. | — | 2014 | → |
| Charcot-Marie-Tooth disease and pathways to molecular based therapies. | Harel T et al. | — | 2014 | → |
| Charcot-Marie-Tooth disease: an overview of genotypes, phenotypes, and clinical management strategies. | El-Abassi R et al. | — | 2014 | → |
| c-Jun activation in Schwann cells protects against loss of sensory axons in inherited neuropathy. | Hantke J et al. | — | 2014 | → |
| Clinical spectrum and gender differences in a large cohort of Charcot-Marie-Tooth type 1A patients. | Colomban C et al. | — | 2014 | → |
| Evolution of Charcot-Marie-Tooth disease type 1A duplication: a 2-year clinico-electrophysiological and lower-limb muscle MRI longitudinal study. | Pelayo-Negro AL et al. | — | 2014 | → |
| Hip dysplasia is more severe in Charcot-Marie-Tooth disease than in developmental dysplasia of the hip. | Novais EN et al. | — | 2014 | → |
| Muscle atrophy in chronic inflammatory demyelinating polyneuropathy: a computed tomography assessment. | Ohyama K et al. | — | 2014 | → |
| Mutation analysis of MFN2, GJB1, MPZ and PMP22 in Italian patients with axonal Charcot-Marie-Tooth disease. | Bergamin G et al. | — | 2014 | → |
| PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies. | van Paassen BW et al. | — | 2014 | → |
| Proximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseases. | Dortch RD et al. | — | 2014 | → |
| The foot and ankle examination. | Papaliodis DN et al. | — | 2014 | → |
| The role of the prefrontal cortex in the development of muscle fatigue in Charcot-Marie-Tooth 1A patients. | Menotti F et al. | — | 2014 | → |
| An essential role of MAG in mediating axon-myelin attachment in Charcot-Marie-Tooth 1A disease. | Kinter J et al. | — | 2013 | → |
| Animal models and therapeutic prospects for Charcot-Marie-Tooth disease. | Bouhy D et al. | — | 2013 | → |
| Anterior tibialis CMAP amplitude correlations with impairment in CMT1A. | Komyathy K et al. | — | 2013 | → |
| A review of genetic counseling for Charcot Marie Tooth disease (CMT). | Siskind CE et al. | — | 2013 | → |
| Early results of the Bernese periacetabular osteotomy for symptomatic dysplasia in Charcot-Marie-Tooth disease. | Stover MD et al. | — | 2013 | → |
| Electrophysiological evaluation of chronic inflammatory demyelinating polyneuropathy and charcot-marie-tooth type 1: dispersion and correlation analysis. | Kang JH et al. | — | 2013 | → |
| Evaluation of dermal myelinated nerve fibers in diabetes mellitus. | Peltier AC et al. | — | 2013 | → |
| Influence of comorbidities on the phenotype of patients affected by Charcot-Marie-Tooth neuropathy type 1A. | Ursino G et al. | — | 2013 | → |
| Inherited peripheral neuropathies. | Saporta MA et al. | — | 2013 | → |
| Joint sparing correction of cavovarus feet in Charcot-Marie-Tooth disease: what are the limits? | Barton T et al. | — | 2013 | → |
| Measuring Ankle Instability in Pediatric Charcot-Marie-Tooth Disease. | Mandarakas M et al. | — | 2013 | → |
| Prolonged high frequency electrical stimulation is lethal to motor axons of mice heterozygously deficient for the myelin protein P₀ gene. | Alvarez S et al. | — | 2013 | → |
| Sonography of the median nerve in CMT1A, CMT2A, CMTX, and HNPP. | Schreiber S et al. | — | 2013 | → |
| The CMT4B disease-causing phosphatases Mtmr2 and Mtmr13 localize to the Schwann cell cytoplasm and endomembrane compartments, where they depend upon each other to achieve wild-type levels of protein expression. | Ng AA et al. | — | 2013 | → |
| The PMP22 gene and its related diseases. | Li J et al. | — | 2013 | → |
| Ultrasonographic nerve enlargement of the median and ulnar nerves and the cervical nerve roots in patients with demyelinating Charcot-Marie-Tooth disease: distinction from patients with chronic inflammatory demyelinating polyneuropathy. | Sugimoto T et al. | — | 2013 | → |
| A novel system to accelerate the progression of nerve degeneration in transgenic mouse models of neuropathies. | Ewaleifoh O et al. | — | 2012 | → |
| A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. | Fledrich R et al. | — | 2012 | → |
| Auditory function in children with Charcot-Marie-Tooth disease. | Rance G et al. | — | 2012 | → |
| Charcot-Marie-Tooth disease and intracellular traffic. | Bucci C et al. | — | 2012 | → |
| Cochlear implantation in a patient with sensori-neural deafness secondary to Charcot-Marie-Tooth disease. | Goswamy J et al. | — | 2012 | → |
| Comparing gait performance of people with Charcot-Marie-Tooth disease who do and do not wear ankle foot orthoses. | Ramdharry GM et al. | — | 2012 | → |
| Comparison between clinical disabilities and electrophysiological values in Charcot-Marie-Tooth 1A patients with PMP22 duplication. | Kim YH et al. | — | 2012 | → |
| Copy number variations in 6q14.1 and 5q13.2 are associated with alcohol dependence. | Lin P et al. | — | 2012 | → |
| Corneal confocal microscopy detects small-fiber neuropathy in Charcot-Marie-Tooth disease type 1A patients. | Tavakoli M et al. | — | 2012 | → |
| Foot drop splints improve proximal as well as distal leg control during gait in Charcot-Marie-Tooth disease. | Ramdharry GM et al. | — | 2012 | → |
| Gas7-deficient mouse reveals roles in motor function and muscle fiber composition during aging. | Huang BT et al. | — | 2012 | → |
| [Guidelines for molecular diagnosis of Charcot-Marie-Tooth disease]. | Berciano J et al. | — | 2012 | → |
| Hand weakness in Charcot-Marie-Tooth disease 1X. | Arthur-Farraj PJ et al. | — | 2012 | → |
| How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease? | Kleopa KA et al. | — | 2012 | → |
| Inherited neuropathies. | Li J | — | 2012 | → |
| Myelin is dependent on the Charcot-Marie-Tooth Type 4H disease culprit protein FRABIN/FGD4 in Schwann cells. | Horn M et al. | — | 2012 | → |
| Neural and molecular features on Charcot-Marie-Tooth disease plasticity and therapy. | Juárez P et al. | — | 2012 | → |
| Neuromuscular function after muscle fatigue in Charcot-Marie-Tooth type 1A patients. | Menotti F et al. | — | 2012 | → |
| Rapid genetic screening of Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies patients. | Li X et al. | — | 2012 | → |
| Axonal Charcot-Marie-Tooth disease. | Shy ME et al. | — | 2011 | → |
| Charcot-Marie-Tooth disease subtypes and genetic testing strategies. | Saporta AS et al. | — | 2011 | → |
| Foot deformity in charcot marie tooth disease according to disease severity. | Joo SY et al. | — | 2011 | → |
| Hereditary peripheral neuropathies of childhood: an overview for clinicians. | Wilmshurst JM et al. | — | 2011 | → |
| Inherited neuropathies. | Schenone A et al. | — | 2011 | → |
| Myelin and axon pathology in a long-term study of PMP22-overexpressing mice. | Verhamme C et al. | — | 2011 | → |
| Nerve conduction studies in Charcot-Marie-Tooth disease in a cohort from Turkey. | Deymeer F et al. | — | 2011 | → |
| New insights into the pathophysiology of pes cavus in Charcot-Marie-Tooth disease type 1A duplication. | Berciano J et al. | — | 2011 | → |
| Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. | Murphy SM et al. | — | 2011 | → |
| Strategy for genetic testing in Charcot-Marie-disease. | Miller LJ et al. | — | 2011 | → |
| Surgical management of pes cavus deformity with an underlying neurological disorder: a case presentation. | Hewitt SM et al. | — | 2011 | → |
| The role of gap junctions in Charcot-Marie-Tooth disease. | Kleopa KA | — | 2011 | → |
| Update on Charcot-Marie-Tooth disease. | Patzkó A et al. | — | 2011 | → |
| 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). | Reilly MM et al. | — | 2010 | → |
| Age-related changes in motor unit number estimates in adult patients with Charcot-Marie-Tooth type 1A. | van Dijk JP et al. | — | 2010 | → |
| Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy. | Vavlitou N et al. | — | 2010 | → |
| Clinical progression in Charcot-Marie-Tooth disease type 1A duplication: clinico-electrophysiological and MRI longitudinal study of a family. | Berciano J et al. | — | 2010 | → |
| Coexistence of two chronic neuropathies in a young child: Charcot-Marie-Tooth disease type 1A and chronic inflammatory demyelinating polyneuropathy. | Marques W et al. | — | 2010 | → |
| Determinants of reduced health-related quality of life in pediatric inherited neuropathies. | Burns J et al. | — | 2010 | → |
| Fatigue, reduced sleep quality and restless legs syndrome in Charcot-Marie-Tooth disease: a web-based survey. | Boentert M et al. | — | 2010 | → |
| Foot pad skin biopsy in mouse models of hereditary neuropathy. | Dacci P et al. | — | 2010 | → |
| Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: a laser-evoked potential study. | Pazzaglia C et al. | — | 2010 | → |
| MUNE and progression of CMT1A. | Shy ME | — | 2010 | → |
| Respiratory muscle weakness in peripheral neuropathies. | Burakgazi AZ et al. | — | 2010 | → |
| Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. | Burns J et al. | — | 2009 | → |
| Ascorbic acid for treatment of CMT1A: the jury is still out. | Shy M | — | 2009 | → |
| Axonal protective effects of the myelin-associated glycoprotein. | Nguyen T et al. | — | 2009 | → |
| Biology of peripheral inherited neuropathies: Schwann cell axonal interactions. | Shy ME | — | 2009 | → |
| Congenital hypomyelinating neuropathy with lethal conduction failure in mice carrying the Egr2 I268N mutation. | Baloh RH et al. | — | 2009 | → |
| Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. | Pareyson D et al. | — | 2009 | → |
| Hereditary predominantly motor neuropathies. | Pareyson D et al. | — | 2009 | → |
| Hip flexor fatigue limits walking in Charcot-Marie-Tooth disease. | Ramdharry GM et al. | — | 2009 | → |
| Identification of the variant Ala335Val of MED25 as responsible for CMT2B2: molecular data, functional studies of the SH3 recognition motif and correlation between wild-type MED25 and PMP22 RNA levels in CMT1A animal models. | Leal A et al. | — | 2009 | → |
| Impaired expression of ciliary neurotrophic factor in Charcot-Marie-Tooth type 1A neuropathy. | Nobbio L et al. | — | 2009 | → |
| Neuromuscular hip dysplasia in Charcot-Marie-Tooth disease type 1A. | Bamford NS et al. | — | 2009 | → |
| PMP22 expression in dermal nerve myelin from patients with CMT1A. | Katona I et al. | — | 2009 | → |
| Screening of the 17p11.2--p12 region in a large cohort of patients with Charcot-Marie-Tooth (CMT) disease or hereditary neuropathy with liability to pressure palsies (HNPP). | Kabzinska D et al. | — | 2009 | → |
| Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A. | Saporta MA et al. | — | 2009 | → |
| The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. | Verhamme C et al. | — | 2009 | → |
| Varying survival of motoneurons and activation of distinct molecular mechanism in response to altered peripheral myelin protein 22 gene dosage. | Nattkämper H et al. | — | 2009 | → |
| Auditory nerve is affected in one of two different point mutations of the neurofilament light gene. | Butinar D et al. | — | 2008 | → |
| Biology and pathology of nonmyelinating Schwann cells. | Griffin JW et al. | — | 2008 | → |
| CMT1A duplication: refining the minimal adult phenotype. | Berciano J et al. | — | 2008 | → |
| Diabetes mellitus exacerbates motor and sensory impairment in CMT1A. | Sheth S et al. | — | 2008 | → |
| Different clinical and magnetic resonance imaging features between Charcot-Marie-Tooth disease type 1A and 2A. | Chung KW et al. | — | 2008 | → |
| Electrophysiology in demyelinating polyneuropathies. | Franssen H | — | 2008 | → |
| Factors that influence health-related quality of life in Australian adults with Charcot-Marie-Tooth disease. | Redmond AC et al. | — | 2008 | → |
| Hypothesis of double polarization. | Li J | — | 2008 | → |
| Magnetic resonance imaging findings of leg musculature in Charcot-Marie-Tooth disease type 2 due to dynamin 2 mutation. | Gallardo E et al. | — | 2008 | → |
| Molecular mechanisms of inherited demyelinating neuropathies. | Scherer SS et al. | — | 2008 | → |
| Motor axon loss is associated with hand dysfunction in Charcot-Marie-Tooth disease 1a. | Videler AJ et al. | — | 2008 | → |
| Neuropathy progression in Charcot-Marie-Tooth disease type 1A. | Shy ME et al. | — | 2008 | → |
| Neurophysiologic abnormalities in children with Charcot-Marie-Tooth disease type 1A. | Yiu EM et al. | — | 2008 | → |
| Remodeling of motor nerve terminals in demyelinating axons of periaxin-null mice. | Court FA et al. | — | 2008 | → |
| Sensory evaluation of the hands in patients with Charcot-Marie-Tooth disease using Semmes-Weinstein monofilaments. | Schreuders TA et al. | — | 2008 | → |
| Treatment for Charcot-Marie-Tooth disease. | Young P et al. | — | 2008 | → |
| Ambulatory disabilities and the use of walking aids in patients with hereditary motor and sensory neuropathy type I (HMSN I). | van der Linden MH et al. | — | 2007 | → |
| CMT1X phenotypes represent loss of GJB1 gene function. | Shy ME et al. | — | 2007 | → |
| Mechanisms of disease: inherited demyelinating neuropathies--from basic to clinical research. | Nave KA et al. | — | 2007 | → |
| Neurodegeneration in multiple sclerosis: defining the problem. | Lisak RP | — | 2007 | → |
| Neuropathic features in fragile X premutation carriers. | Berry-Kravis E et al. | — | 2007 | → |
| Nonmyelinating Schwann cell involvement with well-preserved unmyelinated axons in Charcot-Marie-Tooth disease type 1A. | Koike H et al. | — | 2007 | → |
| Perioperative care of patients with neuromuscular disease and dysfunction. | Brambrink AM et al. | — | 2007 | → |
| Quantified sensory abnormalities in early genetically verified transthyretin amyloid polyneuropathy. | Heldestad V et al. | — | 2007 | → |
| The characteristics of gait in Charcot-Marie-Tooth disease types I and II. | Newman CJ et al. | — | 2007 | → |
| Animal models of Charcot-Marie-Tooth disease type 1A. | Sereda MW et al. | — | 2006 | → |
| Animal models of inherited neuropathies. | Meyer Zu Hörste G et al. | — | 2006 | → |
| Axonal damage and demyelination in long-term dorsal root ganglia cultures from a rat model of Charcot-Marie-Tooth type 1A disease. | Nobbio L et al. | — | 2006 | → |
| Charcot-Marie-Tooth disease type 1A duplication: spectrum of clinical and magnetic resonance imaging features in leg and foot muscles. | Gallardo E et al. | — | 2006 | → |
| Charcot-Marie-Tooth disease type 1A duplication with severe paresis of the proximal lower limb muscles: a long-term follow-up study. | Berciano J et al. | — | 2006 | → |
| Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. | Pareyson D et al. | — | 2006 | → |
| Comparison of CMT1A and CMT2: similarities and differences. | Bienfait HM et al. | — | 2006 | → |
| Major myelin protein gene (P0) mutation causes a novel form of axonal degeneration. | Li J et al. | — | 2006 | → |
| Molecular genetics of autosomal-dominant demyelinating Charcot-Marie-Tooth disease. | Houlden H et al. | — | 2006 | → |
| Myelin disorders: Causes and perspectives of Charcot-Marie-Tooth neuropathy. | Meyer zu Hörste G et al. | — | 2006 | → |
| Overexpression of ErbB2 and ErbB3 receptors in Schwann cells of patients with Charcot-Marie-tooth disease type 1A. | Massa R et al. | — | 2006 | → |
| Peripheral neuropathies caused by mutations in the myelin protein zero. | Shy ME | — | 2006 | → |
| T118M PMP22 mutation causes partial loss of function and HNPP-like neuropathy. | Shy ME et al. | — | 2006 | → |
| Therapeutic strategies for the inherited neuropathies. | Shy ME | — | 2006 | → |
| 17p duplicated Charcot-Marie-Tooth 1A: characteristics of a new population. | Marques W et al. | — | 2005 | → |
| Age associated axonal features in HNPP with 17p11.2 deletion in Japan. | Koike H et al. | — | 2005 | → |
| GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria. | Pedrola L et al. | — | 2005 | → |
| Lack of on-going adaptations in the soleus muscle activity during walking in patients affected by large-fiber neuropathy. | Mazzaro N et al. | — | 2005 | → |
| Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice. | Pan B et al. | — | 2005 | → |
| Reliability and validity of the CMT neuropathy score as a measure of disability. | Shy ME et al. | — | 2005 | → |
| Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. | Li J et al. | — | 2005 | → |
| A novel insertional mutation in Connexin 32 gene causes demyelinating polyneuropathy with predominantly motor axonal loss. | Zhou L et al. | — | 2004 | → |
| A novel stop codon mutation in the PMP22 gene associated with a variable phenotype. | Abe KT et al. | — | 2004 | → |
| Central neural blockade in Charcot-Marie-Tooth disease. | Schmitt HJ et al. | — | 2004 | → |
| Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy Ia. | Verhamme C et al. | — | 2004 | → |
| Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. | Grandis M et al. | — | 2004 | → |
| Loss-of-function phenotype of hereditary neuropathy with liability to pressure palsies. | Li J et al. | — | 2004 | → |
| Sensory manifestations in Charcot-Marie-Tooth disease. | Gemignani F et al. | — | 2004 | → |
| The myelinated axon is dependent on the myelinating cell for support and maintenance: molecules involved. | Edgar JM et al. | — | 2004 | → |
| Assessment of axonal loss in Charcot-Marie-Tooth neuropathies. | Lawson VH et al. | — | 2003 | → |
| Auditory processing in patients with Charcot-Marie-Tooth disease type 1A. | Neijenhuis K et al. | — | 2003 | → |
| Close relationship between motor impairments and loss of functional motoneurons in a Charcot-Marie-Tooth type 1A model. | Norreel JC et al. | — | 2003 | → |
| Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. | Hattori N et al. | — | 2003 | → |
| Demyelinating neuropathies. | Zhou L et al. | — | 2003 | → |
| Disease mechanisms in inherited neuropathies. | Suter U et al. | — | 2003 | → |
| Hereditary neuropathies. | Berciano J et al. | — | 2003 | → |
| Motor unit number estimate of distal and proximal muscles in Charcot-Marie-Tooth disease. | Lewis RA et al. | — | 2003 | → |
| Overwork weakness in Charcot-Marie-Tooth disease. | Vinci P et al. | — | 2003 | → |
| Phenotypic expression of a Pro 87 to Leu mutation in the connexin 32 gene in a large Swiss family with Charcot-Marie-Tooth neuropathy. | Kuntzer T et al. | — | 2003 | → |
| Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. | Shy ME et al. | — | 2003 | → |
| Dejerine-Sottas syndrome grown to maturity: overview of genetic and morphological heterogeneity and follow-up of 25 patients. | Gabreëls-Festen A | — | 2002 | → |
| Hereditary motor and sensory neuropathies: a biological perspective. | Shy ME et al. | — | 2002 | → |
| Inherited neuropathies. | Kleopa KA et al. | — | 2002 | → |
| Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. | Garbern JY et al. | — | 2002 | → |
| Secondary axon atrophy and neurological dysfunction in demyelinating neuropathies. | Hanemann CO et al. | — | 2002 | → |
| The function of the Periaxin gene during nerve repair in a model of CMT4F. | Williams AC et al. | — | 2002 | → |
| Understanding Schwann cell-neurone interactions: the key to Charcot-Marie-Tooth disease? | Maier M et al. | — | 2002 | → |
| A molecular basis for hereditary motor and sensory neuropathy disorders. | Shy ME et al. | — | 2001 | → |
| Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease. | Young P et al. | — | 2001 | → |
| Nerve conduction abnormalities in aging mice deficient for myelin-associated glycoprotein. | Weiss MD et al. | — | 2001 | → |
| Progress in clinical neurosciences: Charcot-Marie-Tooth disease and related inherited peripheral neuropathies. | Benstead TJ et al. | — | 2001 | → |
| The effect of myelinating Schwann cells on axons. | Martini R | — | 2001 | → |
| The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy. | Wang MS et al. | — | 2001 | → |
| Electrophysiological features of inherited demyelinating neuropathies: A reappraisal in the era of molecular diagnosis. | Lewis RA et al. | — | 2000 | → |